Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 8 clinical trials
Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) (SANCTUARY)

The objectives of this study are to evaluate the safety and efficacy of ravulizumab administered by intravenous (IV) infusion compared to placebo and demonstrate proof-of-concept of the efficacy

nephritis
angiotensin
nephropathy
lupus
proteinuria
  • 5 views
  • 04 Oct, 2022
  • 68 locations
A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Dermatomyositis

ravulizumab in adult participants with dermatomyositis (DM).

azathioprine
rituximab
dermatomyositis
methotrexate
corticosteroids
  • 2 views
  • 15 Oct, 2022
  • 33 locations
Ravulizumab and COVID-19

Ultomiris (Ravulizumab), is a monoclonal antibody that specifically targets terminal complement products and is proposed for the treatment of COVID-19 induced microvasculature injury and

monoclonal antibodies
  • 0 views
  • 04 Oct, 2022
  • 1 location
Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD

The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab in pediatric participants with Neuromyelitis Optica Spectrum Disorder (NMOSD).

azathioprine
cyclophosphamide
methotrexate
mycophenolate mofetil
eculizumab
  • 0 views
  • 04 Oct, 2022
  • 1 location
Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (ACCESS 2)

treatment, in patients with PNH who switch from eculizumab or ravulizumab therapy versus patients who continue their eculizumab or ravulizumab therapy The secondary objectives of the study are to

ravulizumab
hemolysis
flow cytometry
fatigue
eculizumab
  • 0 views
  • 25 Mar, 2022
Ravulizumab-Controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Complement Inhibitor Treatment-Naive or Have Not Recently Received Complement Inhibitor Therapy (ACCESS-1)

treatment versus ravulizumab treatment in patients with active Paroxysmal Nocturnal Hemoglobinuria (PNH) who are complement inhibitor treatment-naive or have not recently received complement inhibitor

ravulizumab
hemolysis
flow cytometry
fatigue
complement inhibitor
  • 0 views
  • 26 May, 2022
  • 1 location
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry

Post-marketing safety data on patients treated and untreated with eculizumab or ravulizumab.

  • 203 views
  • 30 Jan, 2022
  • 65 locations
Real Life Use of Ravulizumab in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria

This study will collect clinical response data on participants who were already treated with eculizumab for at least 26 weeks and who started ravulizumab treatment as a specific therapeutic

ravulizumab
hemolysis
neisseria meningitidis
flow cytometry
eculizumab
  • 0 views
  • 04 Oct, 2022
  • 6 locations